Is AI ready for cervical-radiotherapy workflows?
A review of 52 studies finds encouraging automation for contouring, planning and applicator reconstruction. Most evidence remains retrospective and single-centre, with high bias concerns and little independent validation or proof of patient benefit.
The short version
3 key points
- 1.The PRISMA review searched PubMed, Scopus and Web of Science for 2010–2026 evidence, screened 353 records and included 52 studies after full-text review.
- 2.Some models reported Dice similarity scores near or above 0.90 for selected organs or target volumes, but substantial heterogeneity prevented direct comparison and most applications remained proofs of concept.
- 3.Planning, reconstruction and registration evidence frequently had high bias concerns, small single-centre cohorts and no independent external validation. Technical accuracy is not evidence of safer treatment or better survival.
The answer: technically promising, clinically immature
AI can already automate parts of image-guided cervical interventional radiotherapy with impressive results in selected datasets. Across the review, segmentation systems sometimes reached Dice similarity coefficients near or above 0.90 for particular organs at risk or target volumes. Individual studies also reported faster processing, less contouring variation, accurate reconstruction of applicators and useful support for applicator choice. These are meaningful engineering signals in a complex, time-sensitive treatment workflow.
They do not show that an autonomous system is ready to plan or deliver treatment. The 52 studies differed in imaging, anatomy, clinical practice, model design and outcomes, so their headline scores cannot be ranked as a common league table. Most tools were retrospective proofs of concept. Independent multicentre validation and prospective clinical evaluation were rare or absent, and the review repeatedly found high risk of bias in data selection and analysis. A high overlap score is not the same as fewer complications, better local control or longer survival.[1]
How the review assembled the evidence
The authors used PRISMA 2020 and defined the method before searching PubMed, Scopus and Web of Science for original studies published from 2010 through 2026. Eligible work had to evaluate AI in image-guided cervical interventional radiotherapy, the modern form of cervical brachytherapy, including segmentation of targets and organs at risk, treatment planning, applicator reconstruction, image registration or applicator selection. The search found 353 records, removed 127 duplicates and screened 226 titles and abstracts. Sixty-eight full texts were assessed and 52 studies were included.
Quality was evaluated with tools matched to the task. Segmentation, reconstruction and registration studies were assessed as diagnostic-style evidence, while planning and applicator-selection studies were assessed with the 2025 PROBAST+AI framework. That matters because the review did more than collect the best reported scores: it asked whether participants, predictors, reference standards and analyses would support transport into practice. The result is a useful map of technical progress alongside the design weaknesses that limit deployment.[1]
Where AI appears most useful
Segmentation is the most visible application. Clinicians must delineate the tumour and nearby bladder, rectum, bowel and other structures on imaging before calculating dose. Models that generate a reliable first contour could reduce repetitive work and make planning more consistent, provided a qualified clinician reviews every boundary. The best scores were not uniform: structures varied in shape, contrast and imaging protocol, and the review warns that apparently similar Dice values may conceal clinically important errors in different locations.
Planning and reconstruction target different bottlenecks. Planning tools try to predict or optimise a dose distribution, while reconstruction systems identify the implanted applicator and its geometry on scans. Applicator-selection models aim to support a choice before treatment, and registration models align images across time or modalities. Each could shorten work, but each also creates a different failure mode. An inaccurate contour, reconstructed channel or registered image can propagate through the dose calculation, so quality assurance must be task-specific rather than based on a generic AI accuracy label.[1]
Bias concerns are concentrated where deployment matters
For planning studies, 11 of 14 were judged at intermediate risk in the participants-and-data domain, largely because datasets were small, retrospective and single-centre. The analysis domain was the larger concern: limited samples, potentially inadequate independent evaluation, overfitting or leakage and missing external validation. Reconstruction studies were judged predominantly high risk overall, and none had independent external validation. All three image-registration studies had high risk in the index-test domain and no independent external validation.
Applicator-selection studies had the same structural problem. Predictors were often objectively defined and outcomes could be clinically grounded, yet small local datasets and insufficiently independent evaluation left uncertain generalisability. These findings explain why a polished demonstration is not enough. A model can learn scanner settings, annotation habits, applicator brands or patient mix from its development centre. It needs to work when those conditions change and when clinicians encounter difficult cases that were uncommon in the training set.[1]
What this means for patients and clinical teams
For patients, the near-term benefit is more likely to be shorter planning time and more consistent preparation than a fully automated treatment. Any service introducing AI should preserve clinician responsibility, display the generated contour or plan for review and measure corrected errors. Patients should not be told that technical similarity proves a safer or more effective treatment. The review did not establish reductions in toxicity, recurrence, waiting time or inequality of access.
For radiation oncologists, radiographers, physicists and dosimetrists, the central question is where the tool sits in the workflow. Evaluation should include time saved after corrections, disagreement by structure, failure detection, override rates and performance on unusual anatomy. Procurement should require site-specific acceptance testing and monitoring after software or scanner changes. A model that saves ten minutes on routine cases but creates rare undetected dose errors may not be a net improvement.[1]
Evidence limits and what would change the assessment
The review itself is limited by the underlying studies and by publication in an early formatted state. Heterogeneity prevented pooled performance estimates, and favourable technical studies may be easier to publish than unsuccessful replications. Study-level sample sizes and clinical endpoints were inconsistent, so the review cannot identify one model or threshold as ready for universal adoption. The authors reported no financial support or commercial conflict, although one author served on the journal's editorial board and the publisher states that this did not affect review or decision-making.
Confidence would rise with locked models tested prospectively across hospitals, scanners, applicator types and patient populations, using predefined failure rules and independent annotations. Trials should compare AI-assisted and standard workflows on corrected planning time, clinically important contour errors, dose measures, toxicity, local control and staff workload. Until those results exist, the evidence supports supervised workflow research and careful local evaluation—not autonomous treatment planning or claims of improved cancer outcomes.[1]
What this means for people
- Patients may eventually spend less time waiting for planning, but current studies do not show better survival, fewer complications or safe autonomous treatment.
- Clinical teams need task-specific review, override and failure-detection procedures because an error can propagate into dose delivery.
- Hospitals should evaluate corrected time, clinically important errors and patient outcomes, not purchase on Dice scores alone.
Global context
The review spans international research but most models were developed in local clinical datasets. Imaging protocols, applicator hardware, staffing and cervical-cancer pathways differ widely, particularly between well-resourced centres and regions carrying the greatest disease burden.
What the evidence does not yet show
- Large methodological and clinical heterogeneity prevented direct model comparison or meta-analysis
- Many studies were retrospective, small and single-centre
- Independent external and prospective validation was uncommon
- Technical overlap and dose metrics do not establish patient benefit
- Publication bias and inconsistent reporting may overstate maturity
What to watch next
- Prospective multicentre validation of locked models
- Performance across scanners, applicators and underrepresented populations
- Clinically important errors after expert correction
- Effects on planning time, toxicity and local control
- Clear responsibility, override and post-deployment monitoring rules
Living evidence record
Impact record IAI-1X2PV4L
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
15 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what Frontiers in Oncology published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 15 October 2026
Research question, topics and regions
How mature AI systems are for segmentation, planning, reconstruction, registration and applicator selection in image-guided cervical interventional radiotherapy
Topics: Cervical cancer · Brachytherapy · Radiotherapy · Medical imaging · External validation
Regions: Italy · Spain · Europe · Global
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Watch the background, then check the evidence
The Royal Society
AI-generated illustration · not a video frame
YouTube loads only when you choose. Press play in the player to start. If playback is unavailable, use “Watch on YouTube” below.
Healthcare, culture & human impact · Background explainer
Published 2026-07-01 · 44 min 28 sec
Is this the AI future we want? | The Royal Society
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Source checked 14 October 2026. Check available captions on the publisher’s video page.
The Impact Brief · Free
Keep following the stories that matter to you.
Get our weekday briefing on what changed and why it matters. Choose your topics below.
Continue the story
There’s more to this story
Health & Life Sciences
Can brain MRI reveal more than BMI?
A peer-reviewed study trained a deep-learning model on 45,702 MRI scans from six cohorts. Brain-derived features tracked BMI and separated several disease groups better than BMI alone—but the disease analysis stayed inside UK Biobank and cannot establish cause, diagnosis or clinical benefit.
9 min · 2 sources
Health & Life Sciences
Can AI score Crohn disease from a capsule video?
A Shanghai model combined lesion detection with sequence analysis and tracked expert Lewis scores in small internal tests. It sampled only about 7% of a typical video, used one hospital and one capsule system, and has not been tested in a prospective clinical workflow.
7 min · 1 source
Health & Life Sciences
An Alzheimer’s MRI model scored 94.5%. On new data, it fell to 61.6%
For a patient, the important test is whether a model works beyond familiar images. This classifier’s accuracy dropped sharply on an external dataset, and it remains a research system rather than a clinical diagnostic tool.
7 min · 1 source
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.